Optimized dose of hydrogen-enriched water with minocycline combination therapy in experimental ischemic stroke.
Zhao Jiang, Tharun T Alamuri, Darren L Yang, Tyler Annarino, Eric R Muir, Tim Q Duong · Brain research · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In female Sprague-Dawley rats, combination therapy with H₂ and minocycline significantly outperformed H₂ monotherapy in both neurological recovery and infarct reduction, with no sex differences observed. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in female Sprague-Dawley rats. Combination therapy with H₂ and minocycline significantly outperformed H₂ monotherapy in both neurological recovery and infarct reduction, with no sex differences observed.
What the Researchers Studied
The researchers studied female Sprague-Dawley rats. The study used a preclinical animal experiment. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 2.8–3.5 mg/L H₂. Combination therapy with H₂ and minocycline significantly outperformed H₂ monotherapy in both neurological recovery and infarct reduction, with no sex differences observed. The authors concluded that hydrogen-enriched water shows a dose-dependent neuroprotective effect in experimental ischemic stroke, with 20 mL/kg identified as the optimal dose. Molecular hydrogen (H₂) and minocycline (M), both possessing anti-inflammatory and antioxidant properties, have shown individual neuroprotective potential in preclinical models. to enhance the anti-inflammatory and antioxidant effects of hydrogen in combination therapy, a dose of minocycline of 20 mg/kg was selected for this study.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was female Sprague-Dawley rats. The reported sample size was 6. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 2.8–3.5 mg/L H₂.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.